Skip to main content

Cardiac Arrhythmias: New Therapeutic Drugs and Devices

Proceedings of the Symposium on New Drugs and Devices, held at Philadelphia, PA October 4 and 5, 1984

  • Conference proceedings
  • © 1985

Overview

Part of the book series: Developments in Cardiovascular Medicine (DICM, volume 47)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (22 papers)

  1. Basic considerations

Keywords

About this book

In summary, there are many animal models that are useful in selecting new antiarrhythmic drugs. The selection of which model is most idea depends upon precisely what question is being asked. The large number of experimental models used to evaluate antiarrhythmic compounds points out the inability of anyone model to define the probability of antiarrhythmic efficacy in man. It has therefore become standard practice to utilize a batter of animal models for the evaluation of new antiarrhythmic agents. Each model has its own advantages and disadvantages and it is necessary to understand each model fully in oder to evaluate experimental findings and apply them to clinical settings. We believe that the availability of the chronic myocardial infarction ventricular tachyarrhythmia model provides 1) an excellent opportunity to more precisely understand arrhythmia mechanisms, 2) to develop new techniques such as signal averaging for evaluating late low level potentials identifying hearts at high risk of sudden death 3) to identify new antifibrillatory drugs versus drugs that are effective primarily against PVC's and ventricular tachycardia 4) to identify new surgical techniques to eliminate VT/VF, and 5) to evaluate new pacing modalities including implantable cardioverters. Although all animal models are wrong, many are very useful in furthering our knowledge directed at decreasing the distressingly high mortality from heart disease. NORMAL HtART TACHYCMDIA HtART , .. '" \ I I I I I I I I I .

Editors and Affiliations

  • Likoff Cardiovascular Institute of Hahnemann Medical College and Hospital, USA

    Joel Morganroth

  • School of Veterinary Medicine, University of Pennsylvania, USA

    E. Neil Moore

Bibliographic Information

  • Book Title: Cardiac Arrhythmias: New Therapeutic Drugs and Devices

  • Book Subtitle: Proceedings of the Symposium on New Drugs and Devices, held at Philadelphia, PA October 4 and 5, 1984

  • Editors: Joel Morganroth, E. Neil Moore

  • Series Title: Developments in Cardiovascular Medicine

  • DOI: https://doi.org/10.1007/978-1-4613-2595-6

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Martinus Nijhoff Publishing, Boston 1985

  • Hardcover ISBN: 978-0-89838-716-2Published: 30 April 1985

  • Softcover ISBN: 978-1-4612-9626-3Published: 02 October 2011

  • eBook ISBN: 978-1-4613-2595-6Published: 06 December 2012

  • Series ISSN: 0166-9842

  • Edition Number: 1

  • Number of Pages: XII, 356

  • Topics: Cardiology, Pharmaceutical Sciences/Technology

Publish with us